Global NET Patient Survey
Тhe Global NET Patient Survey, a collaborative effort of INCA and Novartis, offered to equip patients with relevant tools to make their voice heard on a new level, as well as to help expert physicians and medical teams understand the challenges/disease burden of NET patients.
“Patient-reported outcomes are the future of medicine.”, said Dr. Simron Singh, medical oncologist at Odette Cancer Center at Sunnybrook Health Sciences Center in Toronto, co-author of NET Survey abstracts and collaborator in the survey results promotion.
Through joining efforts with the top NET experts to promote robust patient-reported data, an unprecedented patient-led collaboration in the NET world was accomplished.
INCA managed to leverage robust data from the survey to engage key audiences at numerous conferences and medical forums.
An article, titled “Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis Results From the First Global Survey of Patients With NETs” was published in the February 2017 issue of The Journal of Global Oncology (download in pdf).
The May-June 2017 issue of The Pancreas, Journal of neuroendocrine tumors and pancreatic diseases and sciences, published the article “Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States, spreading among medical community the US results of the Global NET Patient Survey” (download in pdf).